OCUMENSION THERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.79 HKD | -2.86% |
|
-8.86% | +1.65% |
| Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
| Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 437M 60.51M 473M | Sales 2025 * | 800M 111M 866M | Capitalization | 4.36B 603M 4.71B |
|---|---|---|---|---|---|
| Net income 2024 * | -251M -34.74M -271M | Net income 2025 * | -3M -415K -3.24M | EV / Sales 2024 * | 8.22 x |
| Net cash position 2024 * | 762M 105M 824M | Net cash position 2025 * | 706M 97.71M 763M | EV / Sales 2025 * | 4.56 x |
| P/E ratio 2024 * |
-17.4
x | P/E ratio 2025 * |
-83.7
x | Employees | 444 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 47.57% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -2.86% | ||
| 1 week | -8.86% | ||
| Current month | -5.43% | ||
| 1 month | +18.71% | ||
| 3 months | +36.90% | ||
| 6 months | -7.11% | ||
| Current year | +1.65% |
1 week
6.75
7.47
1 month
5.707.54
Current year
4.517.54
1 year
4.5110.40
3 years
4.5132.05
5 years
4.5143.00
10 years
4.5143.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ye Liu
CEO | Chief Executive Officer | 53 | 18-07-31 |
Tim Ruan
DFI | Director of Finance/CFO | 38 | 23-01-11 |
Dong Hong Chen
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-10-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Li
BRD | Director/Board Member | 52 | 18-03-31 |
Yan Ling Cao
BRD | Director/Board Member | 39 | 19-06-17 |
Ting Yuk Wu
BRD | Director/Board Member | 69 | 20-06-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.59% | 4 M€ | -27.92% | ||
| 0.00% | 0 M€ | +3.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 6.79 | -2.86% | 1,678,018 |
| 24-05-09 | 6.99 | -2.51% | 2,649,000 |
| 24-05-08 | 7.17 | -1.65% | 611,000 |
| 24-05-07 | 7.29 | -0.14% | 1,890,979 |
| 24-05-06 | 7.3 | +2.10% | 2,950,500 |
Delayed Quote Hong Kong S.E., May 10, 2024 at 04:08 am EDT
More quotes
Ocumension Therapeutics is a China-based holding company principally involved in the discovering, developing and commercializing ophthalmic therapies. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The Company conducts its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
6.279
CNY
Average target price
8.653
CNY
Spread / Average Target
+37.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.65% | 603M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- 1477 Stock
